Four H
Four H is a Tokyo-based private health technology company building AI-powered digital therapeutics (xR/VR for MCI, cancer supportive care apps), decentralized clinical trial platforms, and custom healthcare applications for pharmaceutical companies, hospitals, medical device makers, and health enterprises in Japan.
- Company typePrivate
- Founded2020
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Four H does
Four H, Inc. (株式会社Four H) is a Tokyo-based private health technology company founded on June 8, 2020 through the merger of 3H Holdings, a pharmaceutical-industry solutions provider, and HYPER CUBE, a digital healthcare/xR technology firm. The company operates across four pillars: (1) a DTx product line — AI-xR applications including a VR device for Mild Cognitive Impairment, AI-DTx apps for cancer supportive care, and a long-term follow-up system for rare disease gene therapies, with select products targeting medical device certification; (2) clinical trial support systems — a Decentralized Clinical Trial platform comprising Flex EDC, eConsent, telemedicine, and a PHR/EMR-based Clinical Decision Support system for SCR/SDV; (3) an AI Health Tech SIer practice that develops custom healthcare applications using AI, motion capture, wearable devices, and gamification; and (4) Digital Life Science Consulting providing SOP creation, system development, BPO and consultation services for pharmaceutical, medical, and nursing-care clients.
The underlying technology stack combines deep learning for behavioral and health prediction, wearable-device integration for sleep/activity/heart-rate data collection, AI-driven extraction of structured information from PHR/EMR systems, and digital biomarker identification — most notably through a 2023 strategic exploratory partnership with Aculys Pharma for sleep-related diseases (narcolepsy, OSAS). The leadership team combines physicians (including a CMO with 100+ clinical trial protocols as PI), game creators/xR engineers (the COO founded HYPER CUBE), and data scientists, positioning the company to blend medical rigor with engaging product design.
Commercially, Four H generates revenue through a mix of one-time DTx product licenses, professional services for custom application development, consulting fees, and recurring/subscription revenue from clinical trial support systems, sold through direct enterprise engagement to pharmaceutical companies, medical institutions, medical device manufacturers, and broader health-related enterprises in Japan. Registered capital is ¥5.5M, headcount is 11–50, no venture funding rounds are disclosed, and operations remain Japan-domestic only.
Four H firmographics
Firmographics- Name
- Four H
- Legal name
- 株式会社Four H
- Website
- https://four-h.co.jp
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Four H is a Tokyo-based private health technology company building AI-powered digital therapeutics (xR/VR for MCI, cancer supportive care apps), decentralized clinical trial platforms, and custom healthcare applications for pharmaceutical companies, hospitals, medical device makers, and health enterprises in Japan.
- Ownership category
- akta.pro rank
Four H industry classification
Industry- Product category
- Digital Health Software
- NAICS
- Software Publishers (5132), Custom Computer Programming Services (541511)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Programming Services (7371)
- akta.pro primary industry
- DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)
- akta.pro secondary industries
- Condition-specific Digital Therapeutics (DTx) (HLACANAA), Decentralized/Hybrid Trial Enablement (DCT) Platforms (HLACAOAL)
Keywords
Where Four H is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
Four H business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- DTx Product Sales: Development and sales of AI-powered Digital Therapeutics applications for cancer, rare diseases, and CNS disorders. Some products pursue medical device manufacturing/distribution certification/approval.
- Application Development Services (AI Health Tech SIer): Custom application development services using AI, xR, motion capture, and wearable technology for medical, nursing, and clinical trial domains. Includes service design and business model construction.
- Digital Life Science Consulting: Digital transformation consulting for pharmaceutical, medical, and nursing industries including SOP creation, system development, BPO, and consultation services.
- Clinical Trial Support Systems: DCT support systems including EDC, eConsent, and telemedicine platforms. PHR/EMR CDS systems for SCR/SDV support in clinical trials.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Four H product offering
Product offeringCore offering
Four H develops and sells AI-powered Digital Therapeutics (DTx) applications, extended reality (xR) healthcare solutions, and decentralized clinical trial (DCT) support software for pharmaceutical companies, medical institutions, and medical device manufacturers. The company also provides custom application development services (AI Health Tech SIer) and digital transformation consulting for the pharma, medical, and nursing-care industries.
Product overview
Four H is a next-generation health tech company offering a multi-segment portfolio of solutions. The core DTx business develops AI-xR and AI-DTx applications focused on cancer, rare diseases, and central nervous system disorders. The AI Health Tech SIer segment provides application development services using cutting-edge technologies including motion capture, wearables, and gamification for healthcare and clinical trial applications. The Digital Life Science Consulting segment offers end-to-end business process digitization for pharmaceutical, medical, and nursing care industries. The company also develops clinical trial support systems including Flex EDC, eConsent, telemedicine, and PHR/EMR-based Clinical Decision Support systems.
Differentiator
Problem solved
Functional benefit
Products and services
- AI-xR Applications
Quantifiable outcome
- Digital biomarker identification for sleep disorders (narcolepsy, OSAS) including objective sleep patterns, daytime drowsiness patterns, and pre-symptom detection
Companies that use Four H
Customer profileSegments4 records
Ideal customer profiles4 records
Four H technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Four H partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Aculys Pharma (アキュリスファーマ)coreStrategic collaboration with Aculys Pharma for exploratory research on sleep-related diseases (narcolepsy, obstructive sleep apnea syndrome) using wearable devices. Four H provides digital biomarker analysis capabilities and wearable device integration while Aculys Pharma contributes clinical trial expertise. The partnership aims to build a comprehensive sleep ecosystem including objective disease understanding, AI-powered data analysis combining subjective patient evaluation with objective wearable data, and generation of valid and reliable digital biomarker metrics for future clinical trials.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Four H competitors and assessment
Company assessmentBroad incumbents
- Medidata (Dassault Systèmes): Global leader in EDC, eCOA/ePRO, and decentralized clinical trial platforms serving the largest pharma sponsors. Represents the incumbent scale competitor that Four H's Flex EDC must compete against in enterprise deals.
- Clario: Large-scale clinical trial endpoint technology and digital biomarker provider, formed from the merger of ERT and Bioclinica. Comparable in the digital biomarker / wearable clinical data space that Four H is pursuing with Aculys Pharma.
Emerging players
- AppliedVR: VR-based digital therapeutic company with FDA-authorized EaseVRx for chronic pain. Comparable to Four H in its pursuit of VR-based regulatory-grade therapeutics.
- XRHealth: VR/xR-based therapeutic platform for neurological and mental health conditions. Closest direct analog to Four H's AI-xR MCI/central nervous system focus.
- Susmed: Japanese DTx and digital biomarker company developing evidence-based software therapeutics. Comparable in therapeutic-area focus and Japan-centric DTx commercialization.
Direct peers
- Medable: Pure-play DCT platform provider (eCOA, eConsent, telehealth, sensors) used by top-20 pharma. Closely comparable in product scope to Four H's DCT support system.
- CureApp: CureApp is Japan's leading DTx company with PMDA-approved digital therapeutics for nicotine dependence and hypertension. Closest analog to Four H's condition-specific DTx strategy and regulatory pathway.
- MICIN: Japanese health-tech company providing telemedicine, online medical consultation, and decentralized clinical trial infrastructure (MiClinical). Directly comparable to Four H's DCT and clinical trial support capabilities.
- Allm: Allm develops medical communication and healthcare collaboration platforms (Join) and has expanded into DTx. Comparable to Four H in its bridging of communication tools and digital therapeutics for Japanese healthcare.
- Castor: EDC and DCT platform with strong eCRF, eConsent, and remote monitoring capabilities. Comparable to Four H's Flex EDC offering for decentralized and hybrid clinical trials.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Four H financial estimates
Financial estimateRevenue estimate
Valuation estimate
Four H leadership team
Management profileNumber of profiles
Profiles1 record
Four H funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Four H M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Four H
What does Four H do?
Four H develops and sells AI-powered Digital Therapeutics (DTx) applications, extended reality (xR) healthcare solutions, and decentralized clinical trial (DCT) support software for pharmaceutical companies, medical institutions, and medical device manufacturers. The company also provides custom application development services (AI Health Tech SIer) and digital transformation consulting for the pharma, medical, and nursing-care industries.
Is Four H a public or private company?
Four H is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Four H founded?
Four H was founded in 2020. It employs 11 to 50 people.
Where is Four H based?
Four H is headquartered in Tokyo, Japan, in the Asia region.
How does Four H make money?
Four revenue lines are on record. DTx Product Sales are the primary driver. The others are application Development Services (AI Health Tech SIer), digital Life Science Consulting and clinical Trial Support Systems.
Who are Four H's main competitors?
Broad incumbents on record are Medidata (Dassault Systèmes) and Clario. Emerging players are AppliedVR, XRHealth and Susmed. Direct peers are Medable, CureApp, MICIN, Allm and Castor.
Does Four H have an API?
No public API is recorded for Four H.
What industry is Four H in?
Four H's product category is Digital Health Software. Its primary akta.pro industry code is HLACANAO, DTx/SaMD Deployment, Integration & Reimbursement Enablement, with a secondary code of HLACANAA, Condition-specific Digital Therapeutics (DTx). Its NAICS code is 5132 and its SIC code is 7372.